Abstract

Neuropathic pain can result from injury to, or disease of the nervous system. It is notoriously difficult to treat. Peripheral nerve injury promotes Schwann cell activation and invasion of immunocompetent cells into the site of injury, spinal cord and higher sensory structures such as thalamus and cingulate and sensory cortices. Various cytokines, chemokines, growth factors, monoamines and neuropeptides effect two-way signalling between neurons, glia and immune cells. This promotes sustained hyperexcitability and spontaneous activity in primary afferents that is crucial for onset and persistence of pain as well as misprocessing of sensory information in the spinal cord and supraspinal structures. Much of the current understanding of pain aetiology and identification of drug targets derives from studies of the consequences of peripheral nerve injury in rodent models. Although a vast amount of information has been forthcoming, the translation of this information into the clinical arena has been minimal. Few, if any, major therapeutic approaches have appeared since the mid 1990's. This may reflect failure to recognise differences in pain processing in males vs. females, differences in cellular responses to different types of injury and differences in pain processing in humans vs. animals. Basic science and clinical approaches which seek to bridge this knowledge gap include better assessment of pain in animal models, use of pain models which better emulate human disease, and stratification of human pain phenotypes according to quantitative assessment of signs and symptoms of disease. This can lead to more personalized and effective treatments for individual patients. Significance statement: There is an urgent need to find new treatments for neuropathic pain. Although classical animal models have revealed essential features of pain aetiology such as peripheral and central sensitization and some of the molecular and cellular mechanisms involved, they do not adequately model the multiplicity of disease states or injuries that may bring forth neuropathic pain in the clinic. This review seeks to integrate information from the multiplicity of disciplines that seek to understand neuropathic pain; including immunology, cell biology, electrophysiology and biophysics, anatomy, cell biology, neurology, molecular biology, pharmacology and behavioral science. Beyond this, it underlines ongoing refinements in basic science and clinical practice that will engender improved approaches to pain management.

MeSH

Cells, Spinal Cord, Pain, Signs And Symptoms, Cell Biology, Ganglia, Spinal, Therapeutics, Neuralgia, Spinal Cord Dorsal Horn, Spine

Cited by

• Brain-Derived Neurotrophic Factor, Nociception, and Pain. Biomolecules, 2024
• Neural ensembles that encode nocifensive mechanical and heat pain in mouse spinal cord. Nat Neurosci, 2025
• The Intrinsic Neuronal Activation of the CXCR4 Signaling Axis Is Associated with a Pro-Regenerative State in Cervical Primary Sensory Neurons Conditioned by a Sciatic Nerve Lesion. Int J Mol Sci, 2025
• The Mechanism and Inflammatory Markers Involved in the Potential Use of N-acetylcysteine in Chronic Pain Management. Life (Basel), 2024
• How Do Peripheral Neurons and Glial Cells Participate in Pain Alleviation by Physical Activity? Cells, 2025
• A novel approach to completely alleviate peripheral neuropathic pain in human patients: insights from preclinical data. Front Neuroanat, 2025
• Oral Dysaesthetic and Perceptual Disorder, A Distinct Subset of Chronic Orofacial Pain Without Burning Symptoms: A Case-Control Study. J Oral Rehabil, 2025
• The effect of perineural injection therapy on neuropathic pain: a retrospective study. J Dent Anesth Pain Med, 2024
• SPOCK2 modulates neuropathic pain by interacting with MT1-MMP to regulate astrocytic MMP-2 activation in rats with chronic constriction injury. J Neuroinflammation, 2024
• Exploring novel non-opioid pathways and therapeutics for pain modulation. Mol Pain, 2025